T2-high asthma phenotypes across lifespan
Author(s) -
Nicole Maison,
Jimmy Omony,
Sabina Illi,
Dominik Thiele,
Chrysanthi Skevaki,
AnnaMaria Dittrich,
Thomas Bahmer,
Klaus F. Rabe,
Markus Weckmann,
Christine Happle,
Bianca Schaub,
Meike Meyer,
Svenja Foth,
Ernst Rietschel,
Harald Renz,
Gesine Hansen,
Matthias Kopp,
Erika von Mutius,
Ruth Grychtol,
Oliver Fuchs,
Barbara Roesler,
Nils Welchering,
Naschla Kohistani-Greif,
Johanna Kurz,
Katja LandgrafRauf,
Kristina Laubhahn,
Claudia Liebl,
Markus Ege,
Alexander Hose,
Esther Zeitlmann,
Mira Berbig,
Carola Marzi,
Christina Schauberger,
Ulrich M. Zissler,
Carsten B. SchmidtWeber,
Isabell Ricklefs,
Gesa Diekmann,
Lena Liboschik,
Gesche Voigt,
Laila Sultansei,
Gyde Nissen,
Inke R. König,
AnneMarie Kirsten,
Frauke Pedersen,
Henrik Watz,
Benjamin Waschki,
Christian Herzmann,
Mustafa Abdo,
Heike Biller,
Karoline I. Gaede,
Xenia Bovermann,
Alena Steinmetz,
Berrit Liselotte Husstedt,
Cathariitsche,
Vera Veith,
Marlen Szewczyk,
Folke Brinkmann,
Malik Aydin,
Nicolaus Schwerk,
Christian Dopfer,
Mareike Price,
Adan Chari Jirmo,
Anika Habener,
David S. DeLuca,
Svenja Gaedcke,
Bin Liu,
Mifflin-Rae Calveron,
Stefanie Weber,
Tom Schildberg,
Silke van KoningsbruggenRietschel,
Miguel A. Alejandre Alcázar
Publication year - 2022
Publication title -
european respiratory journal
Language(s) - English
Resource type - Journals
eISSN - 1399-3003
pISSN - 0903-1936
DOI - 10.1183/13993003.02288-2021
Subject(s) - medicine , atopy , asthma , immunology , eosinophilia , wheeze , eosinophil , allergy , eosinophil cationic protein , immunoglobulin e , antibody
Rationale In adults, personalised asthma treatment targets patients with T2-high and eosinophilic asthma phenotypes. It is unclear whether such classification is achievable in children. Objectives To define T2-high asthma with easily accessible biomarkers and compare resulting phenotypes across all ages. Methods In the multicenter clinical ALL Age Asthma Cohort (ALLIANCE), 1125 participants (n=776 asthmatics, n=349 controls) were recruited and followed for 2 years (1 year in adults). Extensive clinical characterisation (questionnaires, blood differential count, allergy testing, lung function and sputum induction (in adults) was performed at baseline and follow-ups. Interleukin (IL)-4, IL-5 and IL-13 were measured after stimulation of whole blood with LPS or anti-CD3/CD28. Measurements and Main Results Based on blood eosinophil counts and allergen-specific serum IgE antibodies (sIgE), patients were categorised into four mutually exclusive phenotypes: “Atopy-only”, “Eosinophils-only”, “T2-high” (eosinophilia+atopy) and “T2-low” (neither eosinophilia nor atopy). The T2-high phenotype was found across all ages, even in very young children in whom it persisted to a large degree even after 2 years of follow-up. T2-high asthma in adults was associated with childhood onset suggesting early origins of this asthma phenotype. In both children and adults, the T2-high phenotype was characterised by excessive production of specific IgE to allergens (p<0.0001) and, from school age onwards, by increased production of IL-5 after anti-CD3/CD28 stimulation of whole blood. Conclusions Using easily accessible biomarkers, patients with T2-high asthma can be identified across all ages delineating a distinct phenotype. These patients may benefit from therapy with biologicals even at younger age.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom